Medicare to Negotiate Lower Prices for Weight-Loss Drugs

That would slow the growth of the government’s spending on obesity drugs even as more people on Medicare started using them.

New prices for the 10 drugs in the first round of price negotiations were announced last summer. Those prices will go into effect next year.

Drugmakers were relieved that those cuts were not deeper. They have sued, unsuccessfully, to block the price negotiation program.

---

Drugs Selected for Medicare’s Second Round of Price Negotiations

Prices will go into effect in 2027.

1. Ozempic, Rybelsus and Wegovy, for diabetes and obesity

2. Trelegy Ellipta, for lung conditions

3. Xtandi, for prostate cancer

4. Pomalyst, for blood cancer

5. Ibrance, for breast cancer

6. Ofev, for lung conditions

7. Linzess, for gastrointestinal conditions

8. Calquence, for blood cancers

9. Austedo and Austedo XR, for neurological diseases

10. Breo Ellipta, for lung conditions

11. Tradjenta, for diabetes

12. Xifaxan, for liver and gastrointestinal problems

13. Vraylar, for depression

14. Janumet and Janumet XR, for diabetes

15. Otezla, for inflammatory conditions